pembrolizumab,Cemiplimab
merck,regeneron,sanofi
['gyn', 'cemiplimab']
second-line cemiplimab produces long-term os benefit in recurrent/metastatic cervical cancer #esmo2022 #gyncsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.